Veerhealth Care

13.81
-0.05
(-0.36%)
Market Cap
27.60 Cr
EPS
0.21
PE Ratio
237.63
Dividend Yield
0.00 %
Industry
Healthcare
52 Week High
27.00
52 Week Low
9.29
PB Ratio
1.25
Debt to Equity
0.00
Add Ratio
hide

Investment Returns

In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Competitors LTP Market Cap (₹ Cr.) P/E Ratio Revenue (₹ Cr.) YoY Revenue Growth % Net Profit (₹ Cr.) YoY Profit Growth % RSI
1,712.80
#1 4,10,958.09
36.01
#1 49,887.20
12.06
#1 9,648
13.77
59.55
5,509.05
1,46,247.97
74.00
8,184.00
0.89
1,600
#1 64.53
50.90
1,418.25
1,14,539.99
24.20
26,520.70
14.17
4,155
47.38
55.43
3,262.75
1,10,426.29
59.07
10,785.70
11.59
1,656
13.54
59.71
2,416.60
99,703.73
49.07
10,615.60
19.57
1,942
-16.38
56.35
1,102.80
92,023.74
#1 17.88
28,905.40
12.36
5,578
1.69
45.59
1,989.80
90,842.52
33.34
20,141.50
#1 19.94
1,936
38.82
56.82
865.35
87,074.46
20.00
19,831.50
13.82
3,831
29.92
49.00
1,109.90
64,463.17
19.37
29,559.20
17.55
3,169
-10.04
55.70
29,472.75
62,627.54
47.68
6,097.20
10.80
1,201
16.01
48.49
Growth Rate
Revenue Growth
0.69 %
Net Income Growth
-75.00 %
Cash Flow Change
514.29 %
ROE
-74.80 %
ROCE
10.41 %
EBITDA Margin (Avg.)
14.18 %

Yearly Financial Results

Annual Financials
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
TTM
Revenue
2
3
3
6
6
12
12
11
15
15
15
Expenses
2
2
2
5
6
11
11
10
13
13
14
EBITDA
0
0
0
1
1
1
1
1
2
2
2
Operating Profit %
-12 %
-1 %
-19 %
-2 %
7 %
6 %
1 %
-9 %
4 %
5 %
5 %
Depreciation
0
0
0
0
0
0
1
1
1
1
1
Interest
0
0
0
0
0
0
0
0
0
0
0
Profit Before Tax
0
0
0
0
0
1
1
0
1
1
1
Tax
0
0
0
0
0
0
0
0
-1
1
0
Net Profit
0
0
0
0
0
0
0
-0
2
0
-0
EPS in ₹
0.01
0.00
0.03
0.20
0.23
0.46
0.55
-0.11
1.52
0.21
-0.00

Balance Sheet

Balance Sheet
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
Total Assets
14
14
13
15
16
18
19
20
25
28
Fixed Assets
2
3
3
6
6
10
10
11
12
12
Current Assets
8
7
8
7
3
6
7
6
10
14
Capital Work in Progress
0
0
0
0
2
0
0
0
0
0
Investments
0
0
0
0
0
0
0
0
0
0
Other Assets
12
11
11
9
9
9
9
10
13
16
Total Liabilities
14
14
13
15
16
18
19
20
25
28
Current Liabilities
1
1
-0
1
3
2
2
3
1
3
Non Current Liabilities
1
1
1
0
0
3
3
4
3
4
Total Equity
13
13
13
13
13
14
14
14
21
22
Reserve & Surplus
6
6
6
6
6
7
7
7
11
2
Share Capital
7
7
7
7
7
7
7
7
10
20

Cash Flow

Cash Flow
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
Net Cash Flow
0
0
-0
0
0
-0
0
0
3
-3
Investing Activities
4
0
-0
-3
-2
-2
-0
-1
-2
-0
Operating Activities
-4
0
2
2
2
-0
1
2
-1
3
Financing Activities
0
0
-1
1
0
2
-1
-0
6
-6

Share Holding

% Holding
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Promoter
41.92 %
41.92 %
41.93 %
41.93 %
42.34 %
44.31 %
44.36 %
44.36 %
30.76 %
30.76 %
30.76 %
30.76 %
30.41 %
30.41 %
30.41 %
30.41 %
FIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
DIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
48.78 %
48.53 %
48.11 %
47.50 %
47.42 %
44.95 %
37.12 %
47.81 %
55.14 %
58.28 %
56.23 %
56.80 %
60.05 %
59.25 %
58.57 %
58.53 %
Others
9.29 %
9.55 %
9.96 %
10.57 %
10.24 %
10.73 %
18.52 %
7.83 %
14.10 %
10.96 %
13.01 %
12.44 %
9.54 %
10.33 %
11.02 %
11.06 %
No of Share Holders
3,528
3,517
3,483
3,462
3,642
3,566
3,589
3,655
3,605
3,616
6,195
6,874
10,991
10,255
11,489
11,469

Dividend History

Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %

No dividends have been distributed by the company in the past 10 years

Corporate Action

Announcements

Closure of Trading Window8 days ago
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Mar 07, 2025
Integrated Filing (Financial)Feb 12, 2025
Results-Financial Results For December 31 2024Feb 12, 2025
Board Meeting Outcome for Outcome Of Board MeetingFeb 12, 2025
Board Meeting Intimation for Consideration And Approval Of Unaudited Financial Results Of The Company For The Quarter And Nine Months Ended 31St December 2024Feb 04, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jan 06, 2025
Closure of Trading WindowDec 28, 2024
Announcement Under Regulation 30 (LODR) - Introduction Of New Division In Hospital Care SegmentDec 18, 2024
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationDec 14, 2024
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseDec 12, 2024
Announcement Under Regulation 30 (LODR) - Closure Of Assessment By USFDA Of Form 4003 - FDA Pre-Inspection Records RequestDec 11, 2024
Board Meeting Outcome for Outcome Of Board Meeting For Approval Of Rights Issue Draft Letter Of OfferNov 26, 2024
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseNov 16, 2024
Results-Financial Results For September 30, 2024Nov 14, 2024
Board Meeting Outcome for Outcome Of Board MeetingNov 14, 2024
Board Meeting Intimation for Consider And Approval Of Unaudited Financial Results Of The Company For The Quarter And Half Year Ended 30Th September, 2024.Nov 06, 2024
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018Oct 07, 2024
Shareholder Meeting / Postal Ballot-Scrutinizer''s ReportOct 01, 2024
Shareholder Meeting / Postal Ballot-Outcome of AGMSep 30, 2024
Closure of Trading WindowSep 26, 2024
Announcement under Regulation 30 (LODR)-Investor PresentationSep 18, 2024
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseSep 13, 2024
Announcement under Regulation 30 (LODR)-Award_of_Order_Receipt_of_OrderSep 12, 2024
Announcement under Regulation 30 (LODR)-Newspaper PublicationSep 03, 2024
Book Closure For The Purpose Of 32Nd Annual General Meeting Of The Company.Aug 26, 2024
Reg. 34 (1) Annual Report.Aug 26, 2024
Shareholder Meeting - AGM On September 30, 2024Aug 26, 2024
Announcement Under Regulation 30 (LODR) - Reappointment Of Managing Director And Executive Director Of The CompanyAug 14, 2024
Results-Financial Results For June 30, 2024Aug 14, 2024
Board Meeting Outcome for Outcome Of Board MeetingAug 14, 2024
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseAug 13, 2024
Announcement under Regulation 30 (LODR)-Award_of_Order_Receipt_of_OrderAug 12, 2024
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseAug 08, 2024
Announcement Under Regulation 30 (LODR) - Facility Expansion And New Production CapabilitiesAug 06, 2024
Board Meeting Intimation for Consideration And Approval Of Unaudited Financial Results Of The Company For The Quarter Ended 30Th June, 2024.Aug 06, 2024
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJul 22, 2024
Announcement under Regulation 30 (LODR)-Award_of_Order_Receipt_of_OrderJul 22, 2024
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJul 13, 2024
Announcement under Regulation 30 (LODR)-Award_of_Order_Receipt_of_OrderJul 11, 2024
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018Jul 10, 2024
Closure of Trading WindowJun 26, 2024
Announcement under Regulation 30 (LODR)-Investor PresentationJun 26, 2024
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptJun 19, 2024
'Ayuveer' Products Now Available On Nykaa For PurchaseJun 14, 2024
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeJun 12, 2024
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJun 08, 2024
Announcement Under Regulation 30 Of SEBI LODR - Appointment Of Internal And Secretarial AuditorMay 30, 2024
Results-Financial Results For March 31, 2024May 30, 2024
Board Meeting Outcome for Outcome Of Board MeetingMay 30, 2024

Technical Indicators

RSI(14)
Neutral
53.41
ATR(14)
Volatile
0.94
STOCH(9,6)
Neutral
42.78
STOCH RSI(14)
Overbought
97.18
MACD(12,26)
Bullish
0.30
ADX(14)
Strong Trend
29.25
UO(9)
Bearish
56.53
ROC(12)
Uptrend And Accelerating
10.79
WillR(14)
Overbought
-5.86